IPCA Laboratories share news and announcements
NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap
Last close ₹1,953.30up ₹49.80 (2.62%)BSE ₹1,951.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,903.50.
52-week range of traded prices to 23 Oct 2026
₹1,251.60Low, 24 Oct 2025₹2,038.00High, 18 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹49,556 Cr229th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 37.8
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 6.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 17.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 17.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,18,78151.9% delivered
IPCA Laboratories share news and announcements
771 announcements, routine notices left out, newest first. Page 11 of 16.
Apr 2014
Mar 2014
Jan 2014
Dec 2013
Nov 2013
18 Nov · Updates
Company has entered into an Agreement with M/s. Avik Pharmaceutical Ltd. (Avik) to acquire 50% of its paid-up equity share capital, partly thru purchase of equity shares from its existing shareholders and partly thru subscription to its fresh equity share capital on a preferential allotment basis, both aggregating to approx Rs. 6.51 crores.Avik is an unlisted privately held company which was incorporated in the year 1979 and is currently engaged in the development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) being Steroids and male & female hormones from its manufacturing facilities situated at Vapi in the State of Gujarat.
Oct 2013
24 Oct · Meeting
An Extraordinary General Meeting of the Members of the Company will be held on November 29, 2013, to transact the following business: 1. Re-appointment of Mr. Pranay Godha as the Executive Director of the Company for a further period of 5 (five) years with effect from November 11, 2013; and 2. Increase in the investment limit by Foreign Institutional Investors (FIIs) in the equity share capital of the Company.24 Oct · Dividend
Board of Directors of the Company at its meeting held on October 24, 2013 has declared an interim dividend of Rs. 2.50 per share (125%) for the financial year 2013-14.7 Oct · Corporate action
Company has fixed November 1, 2013 as the 'Record Date' for the Members entitlement of interim dividend for the financial year 2013-14 that may be declared at the Board Meeting to be held on October 24, 2013.7 Oct · Dividend
Dividend if declared shall be paid / dispatched by November 22, 2013.7 Oct · Board meeting
Inter-alia, to consider following: (1) Unaudited Financial Results for the quarter and half year ended September 30, 2013; and (2) Interim Dividend for the financial year 2013-14.
Sep 2013
Aug 2013
Jul 2013
3 Jul · Board meeting
Inter-alia, to take on record the Unaudited Financial Results for the 1st Quarter ended June 30, 2013.
Jun 2013
19 Jun · Meeting
Register of Members and Share Transfer Books of the Company will remain closed from July 23, 2013 to July 30, 2013 (both days inclusive) for the purpose of Annual General Meeting scheduled to be held on July 30, 2013 and for the entitlement of final dividend. Further final dividend if sanctioned will be paid on or before August 20, 2013.
May 2013
30 May · Dividend
Board of Directors of the Company at its meeting held on May 30, 2013 has recommended a final dividend of Rs. 2.00 per share (100%) for the financial year ended March 31, 2013.6 May · Board meeting
Inter alia, to consider : (1) the Audited Financial Results for the financial year ended March 31, 2013; and (2) recommendation of final dividend for the financial year ended March 31, 2013.
Apr 2013
Mar 2013
25 Mar · Management
At the meeting of the Board of Directors of the Company held on March 23, 2013, Mr. Premchand Godha is re-appointed as the Managing Director of the Company for a further period of 5 years with effect from Aprll 01, 2013 subject to compliance with Sections 198, 269, 309, Schedule XIII and other applicable provisions, if any, of the Companies Act, 1956 and also subject to the approval of the Shareholders.
Jan 2013
30 Jan · Business
At the meeting of the Board of Directors of the Company held on January 30, 2013, 48,750 fully paid-up equity shares of Rs.2/- each of the Company @ Rs.63/- per equity share have been allotted upon exercise of options by allotees to whom options were granted on November 11, 2008 pursuant to Ipca Laboratories Limited - Employee Stock Option Scheme 2006 (ESOS). The equity shares now allotted would rank pari-passu in all respects with the existing paid-up equity share capital of the Company. With this allotment, the paid up equity share capital of the Company is now increased to Rs.25,23,98,218/- divided into 12,61,99,109 fully paid-up equity shares of Rs.2/- each.16 Jan · Board meeting
Inter-alia, to consider the following : (1) Unaudited Financial Results for 3rd Quarter and nine months ended December 31, 2012; and (2) Allotment of 48,750 equity shares of Rs.2/- each on exercises of options under Ipca Laboratories Ltd- Employees Stock Option Scheme-2006(ESOS).
Nov 2012
Oct 2012
25 Oct · Dividend
Board of Directors of the Company at its meeting held on October 25, 2012 has declared an interim dividend of 100% (Rs.2/- per share) for the financial year 2012-13.